Psilocybin (1) is a psychoactive natural product found in polyphyletic group of fungi that has been used as an entheogen and hallucinogenic drug. When ingested, psilocybin (1) functions as a prodrug that is rapidly dephosphorylated to psilocin (7). Psilocin, which is the pharmacologically active ingredient is structurally related to a number of similar compounds depicted in Figure 1 such as lysergic acid diethylamide [LSD (2)], N,N-dimethyltryptamine [DMT (3)], and 5-methoxy-N,N-dimethyltryptamine [5-CH$_3$O-DMT (4)], which are all known to induce similar psychoactive effects in humans. A common feature to all of these compounds is their capacity to occasion mystical experiences, which has been correlated with positive therapeutic outcomes. Since the 1960s when Sandoz laboratories supplied psilocybin, the psychiatric community has reported potential implications for treating depression. In contrast to standard antidepressants, which are often taken daily, a single dose of psilocybin has been reported to produce a large antidepressant effect that may last up to six months. Rates of adherence to psilocybin-assisted therapy when administered in supervised and monitored in clinical settings are relatively high compared to standard therapy.

The prevalence of depression has risen in every country and major depressive disorders (MDD) is currently the leading cause of disability worldwide. An estimated 60–70% of suicides in the United States are from people considered clinically depressed. Suicide is one of the top ten causes of death in the United States. This troubling statistic is exacerbated, in part, by opioid addiction, drug overdoses, and MDD. The current treatment for addiction, depression, and anxiety often fail to affect a meaningful quality of life. Consequently, the increase in anecdotal and scientific reports suggesting that psychedelics have therapeutic potential in treatment of these indications have garnered interest in pursuing regulatory changes to enable further research of their clinical use.

To further scientific and clinical research on psychedelics, we embarked on clinical development of psilocybin for the treatment of MDD in participants considered medically healthy and in patients with potentially life-threatening cancer diagnosis. As a result, a practical large-scale synthesis of 1 was needed. Though there were literature precedents that described the synthesis of 1, it became

---

**Abstract**

Described herein is an improved synthesis of 3-[2-(dimethylamino)ethyl]-1H-indol-4-yl dihydrogen phosphate ([psilocybin](https://creativecommons.org/licenses/by-nc-nd/4.0/)). The protocol outlines: synthesis of multigram quantities of psilocybin, identification of critical in-process parameters, and isolation of psilocybin without the use of chromatography, TLC, or aqueous workup. The synthesis furnishes psilocybin in five steps in 23% overall yield from an inexpensive acetoxyindole starting material. With specific focus on process control and impurity fate and removal, the improved procedure is amenable to providing high-quality psilocybin.
critical to modify the procedures in order to provide sufficient quantities of compound with characterization data and quality to meet strict regulatory requirements and support clinical operations.

To date, several syntheses of 1 have been reported. Most commonly, the classical Speeter–Antony tryptamine synthesis (STS) has been used to produce psilocin (7) reliably. The subsequent phosphorylation of psilocin (7) has been historically problematic, owing in part to its labile nature. The use of a benzyl-protected phosphorylating reagent and deprotection has been demonstrated in all previous literature reports. Hofmann first reported the use of O,O-dibenzylphosphoryl chloride in the penultimate phosphorylation step. More recently, Nichols alternatively used tetrabenzyl pyrophosphate (TBPP), citing various undesirable properties of O,O-dibenzylphosphoryl chloride. Furthermore, refinement of the Nichols’ procedure by Shirota was published several years later. In this report, Shirota identified and characterized an unexpected rearrangement product formed by the migration of the O-benzyl group to the dimethylamine functionality (Scheme 1) resulting in a zwitterionic isomer. The limited solubility of zwitterionic intermediate 9 allowed isolation by trituration and simple filtration, which circumvented a difficult chromatographic purification at this step.

In our hands, exact reproduction of the procedure by Shirota fell short of the expected yield and purity. Consequently, we have developed a suitable procedure, which synthesized sufficient quantities of 1 in high purity (99.9%) to support our clinical operations. This report describes potential problems in each step and defines critical process parameters that inform large-scale synthesis of the final active pharmaceutical ingredient (API, 1) in high purity without chromatographic purification.

The general synthetic approach to 1 remained consistent with the previously reported route (Scheme 1), utilizing the classical STS approach from 4-acetoxyindole (5) to obtain 7 with subsequent phosphorylation by TBPP. When benzylated compound 9 was subjected to hydrogenolysis, compound 1 was obtained cleanly.

Starting from acetoxyindole (5), we found that controlling residual oxalyl chloride in the initial acylation reaction was crucial for the stability of intermediate 10 (Scheme 2). In the presence of traces of oxalyl chloride, intermediate 10 decomposes rapidly, which was undesirable for a large-scale campaign where storage of intermediates may last from few hours to days. Additionally, removal of excess oxalyl chloride mitigates a side reaction during the dimethylamine addition, which gave a tetramethyloxamide side-product along with compound 6, which was difficult to remove during purification. Furthermore, the presence of tetramethyloxamide during the lithium aluminum hydride (LiAlH₄) reduction of compound 6 to compound 7, caused excess consumption of LiAlH₄ which led to incomplete reaction and by-products. Using optimized conditions, we found thorough washing of the glyoxal chloride with heptane/MTBE gave clean yellow solid 10 that was stable and stored for several days without decomposition.

In the reaction of dimethylamine with glyoxal chloride 10, ketoamide 6 was conveniently isolated directly from the reaction mixture as a crude solid, which was reslurried with water to remove pyridine salts, followed by heptane and ethyl acetate to remove any additional organic impurities. This process ultimately provided 6 in over 80% yield and 96% purity from 4-acetoxy indole (5). In this form, 6 has been stored for up to several months under ambient conditions with no apparent degradation. Though this material was of sufficient purity to be used in subsequent steps, 6 could be further purified by recrystallization from isopropyl alcohol to afford 70% of a crystalline solid in >99% purity. Compound 6 displays the characteristics of possibly appropriate starting material in current Good Manufacturing Practices (cGMP) because it is readily purifiable, highly stable, and easily characterizable.

Initial attempts at reduction of compound 6 using LiAlH₄ in refluxing THF for 2 hours showed a single chromatographic peak by LCMS with the expected protonated product mass (205), but also an intense signal with 203 (Scheme 3). Attempted isolation of product from this reaction gave an impure material with only low levels of expected signals for compound 7 detectable by NMR. Upon further investigation using analytical HPLC with an optimized

![Scheme 1](image)

**Scheme 1** General synthetic approaches to psilocybin (1)

![Scheme 2](image)

**Scheme 2** Synthesis of 3-[2-(dimethylamino)-2-oxoacyl]-1H-indol-4-yl acetate (6)
gradient, an intermediate with similar retention was detected alongside 7. Under prolonged refluxing in THF (>24 h), this intermediate eventually disappeared and a significant amount of product 7 was seen. Due to stability concerns, prolonged refluxing in THF was ultimately undesirable. Attempts to add excess LiAlH4 during the reaction to affect completion was unfruitful. Fortunately, 2-methyltetrahydrofuran (2-CH3-THF), with a higher boiling point compared to THF, was found to be an acceptable substitute solvent. With good in process control (IPC) by HPLC for reaction monitoring in place, it was determined that after LiAlH4 addition at 0 °C and subsequent warming to ambient temperature, only the major intermediate and approximately 5% of 7 was present in the reaction mixture. The reaction was intentionally stalled at this stage to isolate the intermediate. We found the intermediate impurity to preferentially retain on silica gel and aluminum cake compared to 7. We isolated and analyzed the intermediate by 1H and 13C NMR and found it to be the β-hydroxy compound 11 (Scheme 3).

![Scheme 3 Synthesis of key psilocin intermediate 7](image)

The detected mass signal of 203 (12) from the LCMS analysis of 7 in the crude reaction mixture could be explained by possibly the in-source elimination of the relatively labile hydroxyl group (Scheme 3) during the LCMS run. Furthermore, this elimination process may represent the most likely rate limiting step in the conversion of 11 into 7, given the difficulty of LiAlH4 directly reducing a hydroxyl group. Refluxing for 3 hours in the higher-boiling 2-CH3-THF solvent was sufficient to give a conversion of >95% by HPLC. This was a significant breakthrough that led to the most likely rate limiting step in the conversion of 7 into 9 while minimizing unwanted side reactions given the highly reactive nature of both the tetrabenzyl pyrophosphate (TBPP) and the lithium salt of 7 (Scheme 4).

![Scheme 4 Synthesis of zwitterionic intermediate 9](image)

We found that holding the reaction at −78 °C during butyllithium addition followed by TBPP addition and allowing the mixture to stir for 1.5 hours prior to temperature rise to −20 °C led to clean conversion. The reaction was quenched with ethyl acetate at −20 °C rather than the reported 0 °C, and filtration of the precipitated inorganic solids drowned out compound 8 in the filtrate. The intermediate 8 was suspended in DCM and heated with heat gun for 5 minutes and then slowly cooled to room temperature prior to being held at 0 °C. This process led to complete conversion of 8 into the zwitterionic compound 9. On the other hand, in earlier trial reactions where impure intermediate 8 was utilized, the rearrangement reaction gave incomplete conversions into 9 and took several days to accomplish. Furthermore, if the hot solution was quickly cooled to room temperature, a suspension with very small particle size was obtained, which prolonged filtration time. We obtained complete conversion to crude solid 9, and further trituration with DCM afforded pure compound 9. The color of compound 9 was affected by traces of compound 7, which is prone to oxidation and can
give variable color. In addition, excess TBPP was detrimental to the reaction as it produced phosphate by-products, including dibenzyl phosphate (DBP) that not only impeded conversion into 9 but also affected other downstream processes.

Furthermore, we examined the timing of the reaction, which required several hours from –78 °C to –20 °C, based on our initial findings. We questioned why the very reactive reactants would require such a lengthy timing for completion. To investigate that question, we removed the dry-ice bath after the addition of the TBPP and then rinsed out the dry-ice coating around the round-bottomed flask. We observed suspension of the TBPP at –78 °C, which was indicative of partial solubility of the TBPP at that temperature. We monitored the reaction as it warms up relatively quickly and also removed any ice buildup around the round-bottomed flask. The disappearance of the suspended TBPP correlated to the conversion into 8. At –50 °C, when we observed no traces of suspended TBPP, the reaction was complete in less than 30 minutes. This implies that a solution of TBPP can be added at –50 °C rather than addition of solid TBPP according literature precedents. Controlled addition of substrate is always a preferred protocol on scale, if possible, since it can minimize isothermic reactions. More so, addition of a solution of TBPP makes the protocol amenable to flow chemistry, where both reactants could come in at –50 °C and then a quench line with EtOAc could safely deliver the desired product.

With pure 9 in hand, catalytic hydrogenolysis of 9 to 1 was relatively straightforward. Catalytic hydrogenolysis of 9 was done using 10 wt% Pd/C catalyst under a balloon of hydrogen (1 atm). The reaction was typically complete in 30 minutes (Scheme 5). Compound 1 had low solubility in methanol and during the reaction precipitated from the reaction mixture. Prior to filtration of the catalyst, dilution of the reaction mixture with water helped to solubilize the product.

Reactions were performed using commercially obtained solvents. Unless otherwise stated, all commercially obtained reagents were used as received. 1H and 13C NMR spectra were recorded on a Varian Mercury 400 (at 400 MHz and 100 MHz, respectively) and are reported relative to internal CHCl3 (1H, δ = 7.26), DMSO-d6 (1H, δ = 2.50), CD3OD (1H, δ = 3.31), and CDCl3 (13C, δ = 77.0). DMSO-d6 (13C, δ = 39.5), CD3OD (13C, δ = 49.0). Data for 1H NMR spectra are reported as follows: chemical shift (δ ppm) [multiplicity, coupling constant (Hz), integration]. Standard multiplicity and qualifier abbreviations are used. High-resolution mass spectra were obtained on AB Sciex Triple-TOF 5600+. Preparative HPLC was performed with Waters 2535 Quaternary Gradient Module utilizing XBridge PREP C18 Column 5 µm (30 mm × 250 mm). Analytical HPLC was performed with an Agilent 1100 Series HPLC utilizing Phenomenex Synergi™ 2.5 µm MAX-RP 100Å columns (4.6 mm × 50 mm).

As part of the development of the large-scale manufacture of 1, isolation processes that avoid concentration of solutions to dryness was preferable. This is due to ease of transfer and secondly, stability data indicated degradation of psilocybin (1) to psilocin (7) under prolonged thermal condition in solution. A series of water-miscible anti-solvents were screened that could be used to precipitate 1 from the aqueous solution. Of the solvents tested, acetone emerged as the most attractive. Zwitterionic 1 was virtually insoluble in acetone, which had the additional benefit of also solubilizing minor nonpolar impurities.

Precipitation of 1 from the aqueous reaction mixture using acetone typically provided a semi-crystalline solid in about 90% recovery and 97–98% purity. Encouraged by the anti-solvent properties of acetone and given the moderate solubility of 1 in pure water, we investigated the solvent pair as a recrystallization solvent mixture. It was determined that 80 volumes of a mixture of 30% water in acetone could completely solubilize 1 at reflux. Upon slowly cooling back 0 °C over 6 hours, large colorless crystals formed to provide 1 in 70–80% recovery; HPLC purity analysis of this crystalline solid was typically >99%. Finally, to provide material suitable for clinical use that is free from any inorganic by-products or trace solvent residues, a final recrystallization using pure water was employed, which typically recovered 50–60% product. Full certificate of analysis of this material indicated no detectable impurity.

In summary, we have shown the investigative large-scale synthesis of psilocybin with the goal of identifying and addressing in-process control and critical process parameters like temperature, appropriate solvent, base and so forth, for each step in the synthesis. Furthermore, identification of critical parameters enabled complete conversions of the reactions with minimal side or by-products, which allowed simple purification of product via trituration, filtration, and recrystallization techniques. Finally, the reliable synthesis of compound 7 provides an attractive combination of synthetic/biocatalysis, in which the direct enzymatic phosphorylation of 7 to psilocybin (1) is envisioned. Such synthetic/biocatalytic investigation is ongoing and the report will be presented in due course.
and anhyd Et₂O (700 mL). The flask was resealed with the septum and
flushed with N₂. The suspension was stirred for 10 min and then
cooled to 0 °C in an ice-water bath for 30 min. The dropping funnel
was charged with a solution of oxalyl chloride (37.1 mL, 428 mmol,
1.5 equiv) in Et₂O (60 mL). The oxalyl chloride solution was added
dropwise at a rate sufficient to keep the temperature at or below 5 °C,
to minimize formation of dimer and other possible by-product. As the
addition progressed, a yellow slurry of 10 was formed and when the
addition was completed, the mixture was stirred for 4 h. The comple-
tion of the reaction was assayed by heating an aliquot of the reaction
mixture in MeOH and checking by LCMS the conversion of compound
10 into the corresponding methyl ester [3-[2-methoxy-2-oxoacetyl]-
1H-indol-4-yl acetate]. After this time, heptane (400 mL) was added
and the mixture stirred for 30 min at 0 °C. The yellow solid obtained
was quickly filtered and rinsed successively with heptane (2 × 300
mL), which was quickly used in the next step. Rinsing the solid with
heptane removes excess oxalyl chloride, which prevents the forma-
tion of tetramethoxylaldehyde in the formation of 6. Tetramethyl-
oxalylamide becomes a detrimental impurity, which is difficult to re-
move in the synthesis of 6. Compound 10 was quickly dissolved in
THF (500 mL) and cooled to 0 °C. A 2.0 M solution of dimethylamine
in THF (175 mL) was added dropwise at a rate sufficient to maintain
temperature below 5 °C in order to minimize side reactions. After the
addition was complete, pyridine (46 mL) in of THF (100 mL) was add-
ition was complete, pyridine (46 mL) in of THF (100 mL) was add-
dressed and the mixture was stirred well for 60 min. Heptane
(600 mL) was added and the flask contents were suction filtered via a
Büchner funnel. The filtered residue was transferred into a round-
bottomed flask and deionized H₂O (1000 mL) was added, stirred for
30 min, and filtered via Büchner funnel. The off-white solid was tritu-
ated sequentially for 40 min in EtOAc (600 mL) and heptane (400
mL). The slurry was filtered via Büchner funnel and the solid was
dried in an oven at 40 °C overnight to afford 6 as a light-yellow solid;
yield: 66.1 g (81%); mp 205–207 °C.

IR (KBr): 3236, 1738, 1625, 1428, 1412, 1397, 1217, 854, 772 cm⁻¹.
HRMS (ESI): m/z calcd for C₁₂H₁₆N₂O (M + H)⁺: 205.1338; found:
205.1335.

Compound 11 (β-Hydroxypsilocin)
Intermediate 11 was isolated by performing essentially the same re-
action sequence described for compound 7 on a smaller scale except
it was stirred at rt instead of reflux for 4 h. Following quench, the fil-
trate was concentrated, and the residue was purified by flash column
chromatography (SiO₂, 100:10:1 CH₂Cl₂/CH₃OH/NH₄OH) to provide
11 as a gray solid; mp 172–174 °C.

IR (KBr): 3374, 3257, 1468, 1359, 1242, 1052, 1001, 739 cm⁻¹.
1H NMR (400 MHz, DMSO-d₆): δ = 10.79 (s, 1 H), 7.10 (d, J = 2.4 Hz, 1
H), 6.88 (d, J = 7.7 Hz, 1 H), 6.80 (dd, J = 8.0, 1.1 Hz, 1 H), 6.32 (dd, J =
7.5, 1.0 Hz, 1 H), 5.04 (dd, J = 7.6, 5.0 Hz, 1 H), 3.34 (s, 1 H), 2.58 (dd,
J = 12.5, 7.6 Hz, 1 H), 2.45 (dd, J = 12.5, 5.0 Hz, 1 H), 2.24 (s, 6 H).
13C NMR (100 MHz, DMSO-d₆): δ = 150.83, 139.91, 168.47, 144.26,
139.23, 138.32, 124.72, 118.25, 115.59, 113.44, 110.83, 37.45, 34.20,
21.55.
HRMS (ESI): m/z calcd for C₁₂H₁₀N₄O (M + H)⁺: 203.1335; found:
203.1186.

Procedure B: The reduction step was carried out using essentially the
same protocol described in Procedure A with 6 (40.21 g, 135.2 mmol)
and 2.3 M LiAlH₄ in 2-CH₃-THF (188.1 mL, 432.5 mmol). The reaction
was quenched by dropwise addition of THF/H₂O (27:100, 50 mL) at
a rate that kept the temperature below 30 °C. Anhyd Na₂SO₄ (100 g) was
added followed by silica gel (50 g) and DCM (400 mL). The mixture
was stirred for 10 min and was filtered via Büchner funnel. The filter
cake was quickly dissolved in DCM/CH₃OH mixture (9:1, 1500 mL). The
filtrates were then combined and concentrated to give a light green sol-
olid. The solid was triturated with 1:1 EtOAc/heptane (50 mL), then filtered
via Büchner funnel. The off-white solid was dried in an oven at 40 °C
overnight to provide dry psilocin (7) as an off-white solid; yield:
21.6 g (77%); 99.2% HPLC purity.
Characterization consistent with report in Procedure A.

Benzyl [3-[2-(Benzyldimethylammonio)ethyl]-1H-indol-4-yl] Phosphorate (9)
A 2000 mL four-necked, round-bottomed flask was equipped with
an overhead stirrer, J-Kem temperature controller, a 100 mL dropping
funnel, and rubber septum through which a positive pressure of dry
N₂ inserted. The septum was removed and the flask was charged sequentially with psilocin (7; 10.3 g, 60.2 mmol) and anhyd THF (500 mL). The mixture was stirred for 15 min and the flask was immersed in a solid CO₂/aceton cooling bath at ~78 °C. When the internal temperature of the reaction reached ~67 °C, a solution of 2.5 M BuLi in hexanes (28.9 mL, 72.3 mmol) was added dropwise over a period of a few minutes while maintaining the internal temperature reading below ~60 °C. After stirring the olive-green colored reaction mixture for 10 min, tetrabenzyl pyrophosphosphate (35.7 g, 66.2 mmol) was added in one portion and the mixture was stirred well. After 1.5 h, the solid CO₂/aceton cooling bath was removed and the temperature was allowed to slowly rise to ~25 °C over 2 h, at which time LCMS showed completion of the reaction to compound 15 without any traces of 10 in the reaction mixture. Amino bound silica gel (30 g) was added in one portion and the reaction was diluted with EtOAc (600 mL). The dark mixture was filtered through a pad of Celite and washed with EtOAc (400 mL). The filter cake was resuspended for 10 min with EtOAc (400 mL) and again filtered. The combined filtrates were concentrated and transferred into a 500 mL single-necked round-bottomed flask. The grey oil was redissolved in DCM (100 mL) and heated with a heat gun to boiling for 5 min. The flask was allowed to reach rt and then held at 4 °C overnight. The crude grayish-colored zwitterion precipitate 9 was filtered via Büchner funnel, then triturated with DCM (4 × 100 mL). The zwitterion precipitate 9 was transferred into a 250 mL single-necked round-bottomed flask and thoroughly dried in the vacuum oven at 40 °C overnight to give a light-purple solid; yield: 19.2 g (63%); mp 226–228 °C.

Reference:

1. HNMR (400 MHz, DMSO-d₆): δ = 11.06 (d, J = 2.5 Hz, 1 H), 7.60–7.54 (m, 2 H), 7.53–7.40 (m, 3 H), 7.36–7.25 (m, 4 H), 7.28–7.19 (m, 1 H), 7.09 (t, J = 1.6 Hz, 1 H); 7.01 (dd, J = 14.4, 7.8 Hz, 2 H), 6.91 (t, J = 7.8 Hz, 1 H), 4.85 (d, J = 6.4 Hz, 2 H), 4.68 (s, 2 H), 3.72–3.64 (m, 2 H), 3.41–3.26 (m, 3 H), 3.13 (s, 6 H).

HRMS (ESI): m/z calcld for C₁₂H₁₇N₂O₄P (M + H)⁺: 285.0999; found: 285.0999.

Acknowledgment

The authors wish to thank Dr. Nicholas V. Cozzi, Dr. David E. Nichols, and Dr. Paul Daley for their invaluable insights towards the development of this work.

Supporting Information

Supporting information for this article is available online at https://doi.org/10.1055/s-0039-1691565. Supporting Information

References


2. (a) Dinis-Oliveira, R. J. Drug Metab. Rev. 2017, 49, 84. (b) The LD50/ED50 ratio for aspirin is 199 and 641 for psilocin, which compares favorably to presently approved drugs, see: Paleniecz, T.; Horacek, J. Eur. Neuropsychopharm. 2014, 24, 342.


(16) Reaction monitoring by TLC for this reaction was ambiguous. Even though it showed apparent completion, as it was difficult to distinguish mixtures of 0,0-dibenzylpsilocybin and 0-mono-benzylpsilocybin, see: Nichols, D. E.; Frescas, S. *Synthesis* 1999, 935.

